Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

TNI BioTech Out-licenses Two Drugs to Hubei Qianjiang Pharma

publication date: Oct 19, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
TNI BioTech of the US has out-licensed the China rights for two R&D-stage cancer treatments to Hubei Qianjiang Pharma. TNI’s technology centers on methionine enkephalin (MENK), a cytokine that stimulates the immune system. In IRT-101, MENK is infused directly into the patient. In IRT-102, the treatment consists of isolating a patient's lymphocytes, incubating them with MENK, and then re-infusing them to fight tumor cells. More details....

Stock Symbols: (PINKSHEETS: TNIB) (SHA: 600568)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors